NCT06009874

Clinical Investigation of the Cardioprotective Effect of Early Administration of SGLT2 in Patients Presented With AMI

Clinical Investigation of Cardioprotective Effect of Early Administration of Sodium-glucose Cotransport-2 Inhibitors in Patients With Acute Myocardial Infarction

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 80 (estimated)
• Sponsor: Mohammad Hussien Tantawy Soliman · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

This study aims to investigate the effect of early administration of DAPA during ischemia and before pPCI on infarct size, reperfusion injury-related myocardial damage, cardioprotection from HF, and renoprotection from AKI in patients with AMI.

Detailed description

DAPA was approved for HF patients, but there is no sufficient data about its efficacy on patients with AMI and if it can protect from the development of HF after AMI. the investigators aim to investigate the effect of DAPA on patients who presented with AMI when administered as early as possible before pPCI and to be continued for three months after there. the effect of DAPA on infarct size, cardiac biomarkers will be assessed during the follow-up period

Conditions

• Myocardial Infarction

Interventions

Type	Name	Description
DRUG	Dapagliflozin 10mg Tab	patients will be treated with DAPA 10 mg once daily for three months
DRUG	Placebo	patients will be treated with a placebo tab once daily for three months

Timeline

• Start date: 2023-10-01
• Primary completion: 2026-08-01
• Completion: 2026-08-01
• First posted: 2023-08-24
• Last updated: 2023-08-24

Locations

1 site across 1 country: Egypt